Newly Approved Intelence (Etravirine) Dose May Halve Pill Burden
December 23, 2010
On December 22, 2010, the Food and Drug Administration approved a new 200 mg Intelence (etravirine) tablet. Intelence was originally approved in 2008, in only a 100 mg tablet formulation. The new 200 mg dosage form can help reduce pill burden for patients taking Intelence.
The dosage Dosage and Administration section was changed to state: 200 mg (one 200 mg or two 100 mg tablets) taken twice daily following a meal.
Intelence is a Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI), made by Tibotec Therapeutics.
The revised product label, reflecting the 200 mg tablet approval can be found at www.accessdata.fda.gov/drugsatfda_docs/label/2010/022187s007lbl.pdf.
This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)